Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: A comprehensive review

Drug Safety

Volumn 31, Issue 12, 2008, Pages 1097-1114

  Toovey, Stephen ^a,e   Rayner, Craig ^a   Prinssen, Eric ^a   Chu, Tom ^b   Donner, Barbara ^a   Thakrar, Bharat ^a   Dutkowski, Regina ^b   Hoffmann, Gerhard ^a   Breidenbach, Alexander ^a   Lindemann, Lothar ^a   Carey, Ellen ^c   Boak, Lauren ^d   Gieschke, Ronald ^a   Sacks, Susan ^c   Solsky, Jonathan ^c   Small, Ian ^d   Reddy, David ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE BIOSCIENCE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e NONE   (Switzerland)

Author keywords

Influenza virus infections; Neurological disorders, drug induced; Oseltamivir, adverse reactions; Psychiatric disorders, drug induced

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ABNORMAL BEHAVIOR; ACCIDENT; ACTIVE TRANSPORT; ANXIETY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CAUCASIAN; CHEMOPROPHYLAXIS; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CONVULSION; DATA BASE; DELIRIUM; DELUSION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; ENCEPHALITIS; ENZYME INHIBITION; FEVER; GENERAL PRACTICE; HUMAN; INFLUENZA; JAPANESE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD REVIEW; MENTAL DISEASE; MOLECULAR MODEL; MOTOR ACTIVITY; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PANIC; PARASOMNIA; PERCEPTION DISORDER; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; URINARY EXCRETION;

ACCIDENTS; AGE FACTORS; ANTIVIRAL AGENTS; BEHAVIORAL SYMPTOMS; CLINICAL TRIALS AS TOPIC; DELIRIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INFLUENZA, HUMAN; OSELTAMIVIR; PRODUCT SURVEILLANCE, POSTMARKETING; SUICIDE; WOUNDS AND INJURIES;

EID: 56749106483     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002018-200831120-00006     Document Type: Review

References (44)

1. US FDA. Meeting of the FDA Pediatric Advisory Committee, 16 November 2006 [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/ac/oc06.htm [Accessed 2008 Jul 3]
2. US FDA. Memorandum: Department of Health and Human Services Public Health Service FDA Centre for Drug Evaluation and Research: post-marketing adverse events reports review of central nervous system/psychiatric disorders associated with the use of Tamiflu, September 2006 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006- 4254b_09_01_Tamiflu%20AE%20Review%202006%20Redacted_D060309_092.pdf [Accessed 2008 Jun 30]
3. US FDA. Meeting of the FDA Pediatric Advisory Committee, 27 November 2007 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/07/ transcripts/2007-4325t1_transcript.pdf [Accessed 2008 Jul 3]
4. Fujita T, Mori M, Okumura A, et al. Epidemiologic survey of influenza-associated complications: II. A statistical analysis of symptoms and signs, and medication. J Japan Ped Soc 2007; 111 (12): 2 [online]. Available from URL: http://www.jpeds.or.jp/english/journal/111-12e.html [Accessed 2008 Oct 31]
5. Data on file, Roche, 2008
6. Chung BH, Tsang AM, Wong VC. Neurologic complications in children hospitalized with influenza: comparison between USA and Hong Kong. J Pediatr 2007; 151 (5): e17-8
7. WHO. Suicide Prevention (SUPRE): suicide statistics, last updated 2007 [online]. Available from URL: http://www.who.int/mental_health/prevention/ suicide/country_reports/en/index.html [Accessed 2007 Nov 18]
8. Wilcox M, Zhu S. Oseltamivir therapy appears not to affect the incidence of neuropsychiatric adverse events in influenza patients [abstract]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
9. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 2007; 9 (4): 23
10. Robinson D, Schultz E, Brown P, et al. Updating the Read codes: user-interactive maintenance of a dynamical clinical vocabulary. J Am Med Inform Assoc 1997; 4: 465-72
11. Okumura A, Kubota T, Kato T, et al. Oseltamivir and delirious behavior in children with influenza [letter]. Pediatr Infect Dis J 2006; 25 (6): 572
12. Goshima N, Nakano T, Nagao M, et al. Clinical study of abnormal behaviour during influenza [in Japanese]. Infect Immun Child 2006; 18 (371): 376
13. Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36 (2): 111-6
14. Lin CH, Huang YC, Chiu CH, et al. Neurologic manifestations in children with influenza B virus infection. Pediatr Infect Dis J 2006; 25 (11): 1081-3
15. Huang YC, Lin TY, Wu SL, et al. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J 2003; 22 (4): 366-8
16. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37 (6): 471-84
17. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother 2001; 2 (10): 1671-83
18. Schentag JJ, Hill G, Chu T, et al. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007; 47 (6): 689-96
19. Gieschke R, Dutkowski R, Smith J, et al. Similarity in the pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian children. Options for the Control of Influenza VI; 2007 Jun 17-23; Toronto (ON)
20. Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008; 52: 3687-93
21. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2 (1): 86-98
22. Ose A, Kusuhara H, Yamatsugu K, et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 2008; 36 (2): 427-34
23. Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via Psymptoms glycoprotein. Drug Metab Dispos 2008; 36 (1): 6-9
24. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968; 13 (3): 222-57
25. Chavas LM, Tringali C, Fusi P, et al. Crystal structure of the human cytosolic sialidase Neu2: evidence for the dynamic nature of substrate recognition. J Biol Chem 2005; 280 (1): 469-75
26. Magesh S, Suzuki T, Miyagi T, et al. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors. J Mol Graph Model 2006; 25 (2): 196-207
27. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42 (3): 640-6
28. Monti E, Preti A, Venerando B, et al. Recent development in mammalian sialidase molecular biology. Neurochem Res 2002; 27 (7-8): 649-63
29. Yamaguchi K, Hata K, Koseki K, et al. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem J 2005; 390 (Pt 1): 85-93
30. Hata K, Koseki K, Yamaguchi S, et al. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother 2008; 52: 3484-91
31. Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006; 319 (3): 1477-84
32. Charasson V, Bellott R, Meynard D, et al. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76 (6): 528-35
33. Tanimoto K, Kaneyasu M, Shimokuni T, et al. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics 2007; 17 (1): 1-10
34. Hosokawa M, Furihata T, Yaginuma Y, et al. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 2008; 23 (1): 73-84
35. Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30 (1): 13-9
36. Fujita T, Brown C, Carlson EJ, et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 2005; 15 (4): 201-9
37. Bleasby K, Hall LA, Perry JL, et al. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 2005; 314 (2): 923-31
38. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13 (8): 481-94
39. Sakurai A, Tamura A, Onishi Y, et al. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 2005; 6 (14): 2455-73
40. Ishikawa T, Hirano H, Onishi Y, et al. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 2004; 19 (1): 1-14
41. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005; 2 (1): 73-85
42. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5 (3): 273-82
43. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73 (6): 554-65
44. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280 (10): 9610-7